AtriCure develops and markets treatment solutions for atrial fibrillation. The company’s product lines span all aspects of surgical ablation. Their Synergy RF Ablation System is the first and only device approved by the Food and Drug Administration for the surgical treatment of persistent atrial fibrillation and longstanding persistent atrial fibrillation in patients undergoing open heart procedures simultaneously. Their Cryoablation System is widely accepted for the ease of use and enables surgeons to work fast and accurate. In addition, Atricure pioneered the AtriClip, a left atrial appendage occlusion device that is the most widely implanted for left atrial appendage management worldwide. Early 2014, Atricure completed the acquisition of Estech and continued to implement the ground-breaking technology of the Cobra Fusion into their portfolio.
Link to AtriCure